Previous 10 | Next 10 |
Gainers: Altamira Therapeutics ( CYTO ) +86% . Bullfrog AI ( BFRG ) +26% . Seer ( SEER ) +25% . Ardelyx ( ARDX ) +23% . Lucy Scientific Discovery ( LSDI ) +16% . Losers: Praxis Precision Medicines ( PRAX ) -55% . Veru (...
Seer, Inc. (SEER) Q4 2022 Earnings Conference Call March 2, 2023 4:30 PM ET Company Participants Carrie Mendivil – Investor Relations Omid Farokhzad – Chair, President and Chief Executive Officer David Horn – Chief Financial Officer Conferenc...
Seer press release ( NASDAQ: SEER ): Q4 GAAP EPS of -$0.36 beats by $0.07 . Revenue of $4.6M (+48.4% Y/Y) beats by $0.4M . Revenue was $15.5 million for the year ended December 31, 2022, a 134% increase from $6.6 million for the year ended December 31, 2021. Gros...
REDWOOD CITY, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the fourth quarter and full year ended December 31, 2022. “I am extremely proud o...
Summary Seer went public in December 2020, raising approximately $175 million in a U.S. IPO. The firm is commercializing a proteomics analysis platform. SEER has produced growing revenue from a tiny base and faces a potentially slowing market ahead due to macroeconomic uncertainties...
REDWOOD CITY, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming Cowen 43rd Annual Health Care Conference in Boston, MA. ...
REDWOOD CITY, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the fourth quarter and full year 2022, after market close, on Thursday, Ma...
REDWOOD CITY, Calif., Dec. 27, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming 41 st Annual J.P. Morgan Healthcare Conference. See...
DISCOVERY LIFE SCIENCES LAUNCHES WORLD-CLASS PROTEOMIC SERVICES DIVISION SUPPORTED BY LEADING TECHNOLOGY PARTNERS Canada NewsWire Creates a single source for large-scale population studies, biobank characterization, and multi-omic biomarker analysis to support drug and diagnos...
REDWOOD CITY, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the Proteograph Product Suite has been named one of The Scientist's 2022 Top 10 Innovations , an annual list...
News, Short Squeeze, Breakout and More Instantly...
REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the second quarter 2024 on Thursday, August 8, 2024. Company manag...
Secretome profiles from SpaceX Inspiration4 mission show alterations in oxidative stress, brain homeostasis, and coagulation Creation of first-of-its-kind comprehensive atlas of molecular and physiological multiomic profiles available from multiple spaceflight missions REDWOOD CIT...
REDWOOD CITY, Calif., June 02, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, announced today that PrognomiQ has completed the largest and deepest unbiased mass spectrometry plasma biomarker study to da...